
Non-Sponsored Content
Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved
By: News Feed | Last updated: 2nd July 2018 | In: Gastrointestinal Cancer, Oncology, Targeted Therapies, US FDA Onc\Haem Approvals
Article Keywords
Array BioPharma, binimetinib, BRAF, Braftovi, encorafenib, FDA, Mektovi, melanoma, V600E, V600K
On June 27th, the FDA approved Array Biomarpharma’s combination encorafenib (BRAFTOVI®) plus binimetinib (and MEKTOVI®) for patients with unresectable or metastatic melanoma harbouring a BRAF V600E or V600K mutation detected by an FDA-approved test.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE




































































Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients











































































































© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!